Aurinia Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Aurinia Pharmaceuticals

13/02/2024 13:46

* Aurinia Pharmaceuticals Inc  AUPH.OQ   AUPH.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 15 for the period ending December 31 2023
    * The Victoria British Columbia-based  company is expected
to
report a 56.3% increase in revenue to $44.447 million from
$28.44 million a year ago, according to the mean estimate from 7
analysts, based on LSEG data. (Majority is on Total Revenue
basis)
    * ​LSEG's mean analyst estimate for Aurinia Pharmaceuticals
Inc is
for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $13.00​, above​ its last closing price
of $8.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.16       -0.17      -0.09     Beat    46.2
 Jun. 30 2023  -0.18       -0.18      -0.08     Beat    56.4
 Mar. 31 2023  -0.22       -0.22      -0.18     Beat    18.7​
 Dec. 31 2022  -0.27       -0.27      -0.18     Beat    34
 ​​Sep.        -0.17       -0.17      -0.06     Beat    64.4
 30 2022                                                
 Jun. 30 2022  -0.22       -0.22      -0.25     Missed  -11.9​
 Mar. 31 2022  -0.27       -0.27      -0.27     Met     -1.1
 Dec. 31 2021  -0.27       -0.27      -0.25     Beat    6.9
 This summary was machine generated February 13 at 13:46 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)